iA Global Asset Management Inc. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

iA Global Asset Management Inc. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,922 shares of the biopharmaceutical company’s stock after selling 1,858 shares during the quarter. iA Global Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,268,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $241,000. Daiwa Securities Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 703 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright still reiterated a Buy rating and a $470 price target, signaling the firm remains bullish on Alnylam Pharmaceuticals’ long-term outlook despite trimming near-term estimates.
• Positive Sentiment: HC Wainwright raised its FY2030 earnings estimate to $19.93 per share from $19.65, suggesting confidence in the company’s longer-term growth potential.
• Neutral Sentiment: Barclays also recently initiated or reiterated a Buy stance on Alnylam, adding another supportive analyst view for the stock. Article Title
• Negative Sentiment: HC Wainwright lowered its FY2026 earnings estimate to $6.51 per share from $7.86, implying softer expectations for the current year and potentially pressuring the stock.
• Negative Sentiment: The firm also cut its Q2 2026, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029 EPS forecasts, which may reinforce concerns that near-term profit growth could be slower than previously expected.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada reduced their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Citigroup started coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Finally, Truist Financial decreased their target price on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $461.39.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $301.67 on Thursday. The stock has a market cap of $40.28 billion, a PE ratio of 82.42 and a beta of 0.27. The business has a 50-day simple moving average of $295.37 and a 200-day simple moving average of $329.02. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $273.11 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period last year, the company earned ($0.44) earnings per share. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.